CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors

Chantal L Duurland; Saskia J Santegoets; Ziena Abdulrahman; Nikki M Loof; Gregor Sturm; Tom H Wesselink; Ramon Arens; Sanne Boekestijn; Ilina Ehsan; Mariette I E van Poelgeest; Francesca Finotello; Hubert Hackl; Zlatko Trajanoski; Peter ten Dijke; Veronique M Braud; Marij J P Welters; Sjoerd H van der Burg

doi:10.1136/jitc-2021-003995

Article info

PDF

PDF +
Supplementary
Material

Basic tumor immunology

Original research

CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors

Authors

Chantal L Duurland Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Saskia J Santegoets Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Ziena Abdulrahman Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Nikki M Loof Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Gregor Sturm Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria PubMed articles Google scholar articles
Tom H Wesselink Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Ramon Arens Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Sanne Boekestijn Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Ilina Ehsan Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Mariette I E van Poelgeest Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Francesca Finotello Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, AustriaInstitute of Molecular Biology, University of Innsbruck, Innsbruck, AustriaDigital Science Center (DiSC), University of Innsbruck, Innsbruck, Austria PubMed articles Google scholar articles
Hubert Hackl Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria PubMed articles Google scholar articles
Zlatko Trajanoski Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria PubMed articles Google scholar articles
Peter ten Dijke Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Veronique M Braud Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Université Côte d’Azur, UMR7275, 06560 Valbonne, Sophia Antipolis, France PubMed articles Google scholar articles
Marij J P Welters Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles
Sjoerd H van der Burg Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands PubMed articles Google scholar articles

Citation

Duurland CL, Santegoets SJ, Abdulrahman Z, et al

CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors

Journal for ImmunoTherapy of Cancer 2022;10:e003995. doi: 10.1136/jitc-2021-003995

Online issue publication

October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password